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Abstract.
Background: TERT promotor mutations are present in >75% of bladder tumours; these mutations are also detectable in urine.
Previous studies have used urinary pellet DNA, and semi-quantitative methods unsuitable for detecting very low mutant allele
frequencies.
Objective: In this proof-of-principle study we use ddPCR to count the DNA molecules with wt and mutant TERT sequences
in urinary cfDNA from patients whose bladder cancers harbour TERT mutations.
Methods: Urinary cfDNA prepared from the urine from 104 bladder cancer patients was analysed. We determined the mutant
allele frequency across stages and grades of disease, analysed concordance between cfDNA and tumour DNA, compared
cfDNA with pellet DNA, and analysed the quantity and size distribution of cfDNA.
Results: In 71 of 77 patients with a 228 G>A/T mutant tumour, the mutation was also detected in urinary cfDNA by ddPCR;
all 6 “false negatives” were low grade pTa tumours. Overall concordance between tissue and cfDNA mutation status was 92%,
and 100% was achieved for high grade disease. Median mutant allele frequencies in urinary cfDNA were 3.4, 13.4 and 32.1%
in grade 1, 2 and 3 disease. The 228 G>A/T mutation was not detected in urinary cfDNA in 26 out of 27 mutation-negative
patients (96% specificity).
Conclusions: Concordance between tumour DNA and urinary cfDNA is high, and TERT 228 G>A/T ddPCR may prove
useful for monitoring patients that harbour this mutation. Mutant allele frequencies in cfDNA are often high, but assays
capable of detecting very low mutant allele frequencies will be required to achieve high sensitivity in low grade disease.
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INTRODUCTION
The current gold standard method for urothelial
bladder cancer (UBC) detection in both the inci-
dent and surveillance settings is cystoscopy. Much
research has focused on reducing dependence upon
this burdensome and expensive investigation by
searching for urinary biomarkers which might enable
non-invasive detection. Such biomarkers might even
permit surveillance via urine samples collected in
patients’ own homes.
Historically, urinary biomarker research has
focussed on proteins and whilst work continues on
developing panels of proteins with sufficient diag-
nostic accuracy, most proteins lack the sensitivity
and specificity required for clinical utility [1]. Other
classes of biomarkers such as mRNA and miRNA
profiles and volatile organic compounds show
promise; however, recently DNA-based biomarkers
have come to the fore driven by technological
developments and an increased understanding of the
genomic and epigenetic mechanisms underpinning
UBC (reviewed in [2]). Bladder cancer is a heteroge-
neous disease so it is likely that a panel of biomarkers
will be required to achieve high sensitivity [3, 4].
Detection of copy number changes, somatic muta-
tions and DNA methylation in urine DNA have
provided encouraging results [5–9]. Nonetheless,
significant challenges remain to achieve clinically
acceptable sensitivity and specificity: although urine
should be an ideal source of biomarkers due to its
direct contact with the tumour, extracting sufficient
usable DNA from urine samples can be difficult,
and the proportion of that DNA which originates
from the tumour is variable. The optimal analytical
platform must therefore be able to cope with both low
nanogram quantities of input DNA and low mutant
allele frequencies. In addition, all the components of
a multimarker test would ideally be measurable using
a single robust, rapid and inexpensive assay platform.
In 2013, mutations in the TERT promotor at
position –124 and –146 bp relative to the TERT tran-
scription start site were reported to be common events
in UBC [10–13]. The mutations are at positions
chr5:1,295,228 and chr5:1,295,250 (hg19), hereby
referred to as “228” and “250”. The 228 G>A is a
particularly strong biomarker candidate as this single
base substitution has been reported to be present in
53–66% of UBCs, and across all stages and grades of
disease [12, 14, 15]. Several studies have reported the
detection of TERT promotor mutations in DNA from
urine cell pellets [7, 10, 16, 17]. However, there is evi-
dence that urinary cfDNA may more faithfully reca-
pitulate whole tumour DNA than the more commonly
used urinary cell pellet DNA [9, 18, 19]. The high fre-
quency of TERT mutations in UBC make them key
constituents of any somatic mutation panel for detect-
ing primary UBC; a large mutation panel including
TERT mutations may be required for detecting pri-
mary disease but following index tumour sequencing
a smaller personalised mutation panel could suffice
for surveillance and TERT mutations would be use-
ful for the majority of patients. We hypothesise that
because of the number of mutations required, a large
panel for initial detection is likely to be next gener-
ation sequencing (NGS) based [7], whereas smaller
personalised panels for surveillance could be based
on digital droplet PCR (ddPCR) with its ability to
detect very low mutant allele frequencies but limited
ability to detect multiple mutations [19, 20].
In this study, we investigate the use of digi-
tal droplet PCR for the TERT 228 G>A mutation
to determine mutant allele frequency and hence
“tumour burden” in urinary cfDNA and compare with
cell pellet DNA and tumour DNA next generation
sequencing data. We also characterise the size and
quantity of DNA across different stages and grades
of bladder cancer. We conclude that the application
of TERT mutation ddPCR to urinary cfDNA warrants
further examination as a personalised assay for the
surveillance of UBC patients whose tumours harbour
this mutation.
MATERIALS AND METHODS
Patients and specimens
Urine and tissue specimens were prospectively col-
lected for biomarker research between 2006 and 2011
as part of the Bladder Cancer Prognosis Programme
(BCPP, ethics approval 06/MRE04/65) [21]. All UBC
patients were newly-diagnosed and had not received
treatment prior to urine or tissue collection. Inclusion
and exclusion criteria are detailed elsewhere [21].
Urine specimens were placed on ice, centrifuged at
2000 g for 10 minutes within 8 hours of collection,
and supernatants and pellets stored at –80◦C. Tissue
specimens were collected at the time of transurethral
resection, snap-frozen in liquid nitrogen and stored
at –80◦C.
DNA was extracted from 135 paired frozen
tumours and urine supernatants (cfDNA); DNA was
also extracted from 17 accompanying urine pellets.
The 135 patients were selected from the larger BCPP
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study on the basis that they were within the 50%
of BCPP tumours subjected to targeted NGS and
hence with known TERT mutation status (manuscript
in preparation) and had >10 ml of urine supernatant
available for cfDNA preparation. No attempt was
made to select on the basis of stage or grade.
Tumour next generation sequencing
DNA was extracted from 25 mg frozen tissue using
the DNeasy Blood and Tissue kit (Qiagen, #69506).
The TERT promotor mutation status of every tumour
was determined by targeted next generation sequenc-
ing as described previously [7].
Urine ddPCR
Approximately 50 ml of urine was processed per
patient, with 10 ml of urinary supernatant or the
entire pellet utilised for DNA extraction using the
Quick-DNA Urine kit (Zymo, D3061). DNA con-
centrations were determined using the Qubit high
sensitivity DNA kit (Thermo, #Q32854) and cfDNA
size determined by Bioanalyzer using high sensitivity
chips (Agilent, # 5067-4626). cfDNA preparations
from 104 patients yielded >10 ng DNA and were
included for analysis. The overall study design and
patient demographics are shown in Supplemental
Figure S1 and Table S1. The number of wt and
TERT 228 G>A/T DNA molecules was determined
in all urinary DNAs and 21 of the tumour DNAs
by digital droplet PCR using the TERT C228T liq-
uid biopsy assay (Thermo, #A44177), supermix for
probes (Biorad, #1863010) and the Biorad QX200
droplet formation/reader system (Biorad). The PCR
program consisted of 10 minutes at 96◦C followed
by 54 cycles of 98◦C × 30 sec and 55◦C × 2 min.
Log rank tests were used to compare data across
patient groups.
RESULTS
Assay validation
The TERT promotor sequence is both repetitive
and GC rich; in our experience, many polymerases
fail to amplify this region. We therefore commenced
by comparing the levels of TERT mutation found by
ddPCR versus an established NGS workflow [7] in
DNA extracted from 21 fresh-frozen tumours. As
shown in Fig. 1A, good agreement between the 2
methods was observed. We found that the ddPCR
assay yields a positive result with the less common
228 G>T mutation as well as the 228 G>A mutation.
The ddPCR assay also performed well in a serial
dilution of mutant DNA (Fig. 1B).
cfDNA analysis of urinary DNA
ddPCR was used to analyse urinary cfDNAs from
104 UBC patients. All of these patients had the TERT
promotor sequenced in their tumour DNA by NGS
(12 × wt, 15 × 250A, 75 × 228A and 2 × 228T). The
mutant allele frequency as determined by ddPCR is
shown for every cfDNA analysed in Fig. 2. cfDNA
from the 27 patients with tumours negative for a
228 mutation gave very low levels of mutant posi-
tive droplets and allowed us to define a threshold of
Fig. 1. ddPCR validation. Figure 1(A) shows the TERT 228 G>A/T mutant allele frequency in DNA extracted from 21 fresh-frozen bladder
tumours measured by ddPCR and NGS. Figure 1(B) shows ddPCR analysis of a 2-fold serial dilution of pooled TERT mutant tumour DNA
(15% mutant by NGS) diluted in pooled TERT wt tumour DNA.
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Fig. 2. TERT 228 G>A/T mutant allele frequencies in the cfDNA of 104 UBC patients. The mutant allele frequency for each patient in the
study is represented by a single bar. Patients are sorted within each group by mutant allele frequency. The groups are: UBCs with wt TERT
promotor, UBCs with TERT 250 G>A mutant promotor and UBCs with TERT G > 228A/T separated into pTa, pT1 and pT2 + disease.
1% mutant allele frequency (MAF) for a “positive
result” (mean + 2SD). The cfDNA result from 26 of
the 27 wt or 250 G>A tumours were below this thresh-
old. Analysing the cfDNA from patients with a TERT
228 G>A/T positive tumour by NGS gave a positive
result in 71 out of 77 cases (92%): 24 of 30 mutant
positive pTa tumours (80%) gave a positive result,
and all pT1 (n = 19) and MIBC (n = 27) cases gave
a positive result. All 6 “false-negative” results were
from patients with grade 1 pTa disease, and there were
no false-negatives amongst higher grades and stages.
The cfDNA MAF data is summarised in Fig. 3. These
data show that MAF is strongly influenced by tumour
grade and size, but less so by stage of disease, cfDNA
concentration or the number of tumours.
ddPCR analysis of urinary cfDNA and cell pellet
DNA
Figure 4 plots the TERT MAF detected by ddPCR
for 17 paired cfDNAs and cell pellet DNAs (both
types of DNA extracted from the same urine void).
There is a positive correlation between tumour
content in the two types of DNA (r2 = 0.73), although
there is also scatter in the data indicating that the MAF
in the two types of DNA may differ in any individ-
ual patient. The average MAF was not significantly
different between cfDNA and pellet DNA.
Quantification and size analysis of urinary
cfDNA in UBC patients
cfDNA was prepared from 10 ml of each urine
supernatant. The median yield of cfDNA was 39 ng
(3.9 ng/ml urine); however, yield was highly variable
and 10 samples yielded less than 1 ng of cfDNA.
Yield was dependent on the stage, grade and size but
not the number of tumours (Fig. 5). The Bioanalyzer
gel electrophoresis system was used to analyse the
size distribution of urinary cfDNA in UBC patients.
The vast majority of samples presented with a peak
of approximately 178 bp consistent with mononu-
cleosomal cfDNA (Fig. 6). Di- and trinucleosomal
DNA was also evident in most samples along with
a variable amount of longer DNA (1–10 kb). The
ratio of 178 bp DNA to longer fragments was highly
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Fig. 3. TERT mutant allele frequencies in cfDNA. The 6 panels show the influence of, A: tumour mutation status, B: tumour grade, C:
tumour size, D: disease stage, E: cfDNA concentration (</>median level) and F: number of tumours on cfDNA TERT mutant allele frequency
determined by ddPCR.
variable although on average 50% of the intensity
of the Bioanalyzer traces was >300bp. We found
no relationship between the ratio of 178 bp DNA
to longer fragments and MAF suggesting that the
tumour:normal ratio is similar in both types of DNA
and that targeting urinary cfDNA of a particular size
category would not aid in biomarker detection. To
corroborate this result, we applied Pronex bead frac-
tionation (Promega) to 8 of the higher concentration
cfDNAs. This method produced 2 fractions for each
sample: one enriched for shorter fragments and one
enriched for longer fragments (Figure S2 Supplemen-
tal Information). There was no significant difference
in the TERT MAF measured by ddPCR in the 2
fractions.
DISCUSSION
We have used ddPCR to count the number of wt
and TERT 228A mutant molecules in the urinary
cfDNA of patients with varying stages and grades
of UBC. In patients whose tumours contained the
TERT 228 G>A/T mutation, we were able to detect
the mutation in urinary cfDNA with a sensitivity of
92%. It is therefore likely that the combination of
ddPCR and cfDNA for this common mutation in
Fig. 4. Comparison of mutant allele frequencies in urinary cfDNA
and cell pellet DNA. 17 paired samples were analysed by ddPCR.
bladder cancer could play a role in disease surveil-
lance. It should be noted that 31 patients had <10 ng
of DNA extracted from the 10mls of urine, and were
excluded from the analyses. Thus, the reported sensi-
tivities and specificities relate only to those samples
which did generate enough DNA to be assayed. The
excluded patients comprised 4 MIBC, 5 pT1 and 22
pTa and had a mean tumour diameter of 2.7 cm (com-
pared with 3.7 cm for the remainder of the cohort).
DNA extraction from a larger volume of urine would
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Fig. 5. Factors which influence urinary cfDNA concentration. All DNA concentrations were determined using the Qubit HS double-stranded
DNA kit. Figure A) the effect of tumour grade on urinary cfDNA, B) effect of stage, C) effect of tumour size, D) effect of the number of
tumours.
likely resolve this issue. We found that the assay
detects both G > A and G > T substitutions at position
228 (but not at the 250 position), and that 74% of the
patients in this study had one or other substitution at
position 228.
We envisage that index tumour sequencing is likely
to be routine in the not too distant future and that this
would enable selection of a small panel of somatic
mutations for personalised non-invasive surveillance.
Such panels could be ddPCR based and the TERT
228 G>A/T mutation would be a core component for
many patients. Although limited in its ability to mul-
tiplex biomarkers, ddPCR is well suited to detecting
rare mutations and is inexpensive, fast, reliable and
gives absolute quantitation [22]. Tumour evolution
might compromise the use of mutations for surveil-
lance; however, in NMIBC recurrences occur as a
result of incomplete resection of the primary urothe-
lial cancer, tumour cell re-implantation, growth of
microscopic tumours present at the time of the pre-
vious resection, or genuine new tumour formation
[23]. Although bladder cancer is a heterogeneous
disease, it is also a disease in which synchronous and
metachronous tumours demonstrate “clonality” [2].
Thus, it can be reasonably assumed that mutations
in the primary index tumour will remain as charac-
teristics of new tumours and be detectable in body
fluids, as others have demonstrated [19, 20, 24]. In
the specific case of TERT, mutations are considered
to be early events in bladder carcinogenesis and are
frequent across all stages of disease suggesting that
loss of TERT mutations during tumour evolution is
rare [14]. Moreover, Brown et al recently reported
that TERT mutations are conserved both spatially
and temporally in UBCs [25]. Additional benefits
of facile TERT mutation detection via urinary DNA
could include treatment selection and prediction of
recurrence and survival [12, 16, 26].
We found that the MAF in urinary cfDNA is sur-
prisingly high (median = 18%), but high inter-patient
variability is observed and levels are much lower
in low grade disease. We also analysed the size of
urinary cfDNA and found that whilst both mononu-
cleosomal and longer DNA fragments are present in
variable proportions, both appear to contain tumour
DNA. Our data suggest that an analytical method with
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Fig. 6. Bioanalyzer analysis of urinary cfDNA from UBC patients. Each trace is for a cfDNA from a different patient. The traces show the
amounts of 1: mononucleosomal, 2: di- and tri-nucleosomal and 3: longer (1–10 kb) DNA fragments.
a limit of detection of 1% mutant allele frequency
would detect most grade 2 and 3 tumours, but that an
even higher analytical sensitivity is required to detect
elusive grade 1 cases. In principle, ddPCR should
allow detection of mutant alleles at much lower than
1% frequency; however, in our hands a small number
of TERT mutation positive droplets were detected in
DNA derived from patients with TERT wt tumours
(see Figure S3) and this background “noise” limits
analytical sensitivity. The positive droplets could be
due to PCR errors arising from the GC-rich nature of
the TERT-promotor, sample contamination, or possi-
bly in some cases, sub-clonality, i.e. TERT mutations
in areas of the tumour or urothelium that were not
sequenced.
In contrast to previous studies favouring urinary
cfDNA over pellet DNA for recapitulating tumour
genomics [9, 18, 19], the limited comparison of
urinary cfDNA and cell pellet DNA in this study
(n = 17, Fig. 4) did not show a clear advantage to
using cfDNA over pellet DNA for the detection of
the TERT 228 G>A/T mutation. In this scenario, the
higher DNA yield typically achieved from cell pellets
may favour their use in diagnostic testing: larger scale
studies are required for comprehensive comparison of
the two sources of DNA.
In conclusion, ddPCR detection of TERT muta-
tions in urinary cfDNA holds promise for the
non-invasive detection of UBCs known to harbour
these mutations (approximately three quarters of all
patients). The current work has analysed urinary
cfDNA from more individual patients than previous
studies and adds to a body of evidence supporting
urinary cfDNA as a suitable substrate for the non-
invasive detection of UBC [9, 18–20].
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